share_log

中基長壽科學:截至二零二四年六月三十日止六個月中期業績公告

ZHONG JI LS: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024

HKEX ·  Aug 28 10:46
Summary by Moomoo AI
中基長壽科學集團有限公司公布截至2024年6月30日止六個月的未經審核中期業績,顯示收益增加41.8%至42.4百萬港元,毛利增加25.6%至33.3百萬港元,但除稅前溢利減少85.9%至0.7百萬港元。淨資產輕微增加至432.1百萬港元,並未建議派付中期股息。公司主要業務包括長壽科學業務、借貸及金融諮詢業務、證券及其他投資以及物業投資。期內,長壽科學業務收益約為25.18百萬港元,而借貸及金融諮詢業務收益為17.22百萬港元。公司股份於香港聯合交易所有限公司上市,並於期內加強長壽科學業務的發展,包括與賽默飛世爾科技(香港)有限公司建立戰略合作夥伴關係。報告期後,公司未有重大事項發生。
中基長壽科學集團有限公司公布截至2024年6月30日止六個月的未經審核中期業績,顯示收益增加41.8%至42.4百萬港元,毛利增加25.6%至33.3百萬港元,但除稅前溢利減少85.9%至0.7百萬港元。淨資產輕微增加至432.1百萬港元,並未建議派付中期股息。公司主要業務包括長壽科學業務、借貸及金融諮詢業務、證券及其他投資以及物業投資。期內,長壽科學業務收益約為25.18百萬港元,而借貸及金融諮詢業務收益為17.22百萬港元。公司股份於香港聯合交易所有限公司上市,並於期內加強長壽科學業務的發展,包括與賽默飛世爾科技(香港)有限公司建立戰略合作夥伴關係。報告期後,公司未有重大事項發生。
Zhong Ji Changshou Scientific Group Limited announced its unaudited interim results for the six months ended June 30, 2024, showing a 41.8% increase in revenue to HK$42.4 million, a 25.6% increase in gross profit to HK$33.3 million, but a 85.9% decrease in profit before tax to HK$0.7 million. Net assets slightly increased to HK$432.1 million, and no interim dividend was proposed. The company's main businesses include long-life science business, lending and financial consulting business, securities and other investments, and property investments. During the period, the revenue of the long-life science business was approximately HK$25.18 million, while the revenue of the lending and financial consulting business was HK$17.22 million. The company's shares are listed on The Stock Exchange of Hong Kong Limited and have strengthened the development of the long-life science business during the period, including establishing a strategic partnership with Thermo Fisher Scientific (Hong Kong) Limited. After the reporting period, there were no significant events occurring.
Zhong Ji Changshou Scientific Group Limited announced its unaudited interim results for the six months ended June 30, 2024, showing a 41.8% increase in revenue to HK$42.4 million, a 25.6% increase in gross profit to HK$33.3 million, but a 85.9% decrease in profit before tax to HK$0.7 million. Net assets slightly increased to HK$432.1 million, and no interim dividend was proposed. The company's main businesses include long-life science business, lending and financial consulting business, securities and other investments, and property investments. During the period, the revenue of the long-life science business was approximately HK$25.18 million, while the revenue of the lending and financial consulting business was HK$17.22 million. The company's shares are listed on The Stock Exchange of Hong Kong Limited and have strengthened the development of the long-life science business during the period, including establishing a strategic partnership with Thermo Fisher Scientific (Hong Kong) Limited. After the reporting period, there were no significant events occurring.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more